Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Mazyar Shadman, Sangeeta Hingorani, Scott A. Lanum, John M. Pagel, Rainer Storb, David G. Maloney & Brenda M. Sandmaier. (2017) Allogeneic hematopoietic cell transplant for patients with end stage renal disease requiring dialysis – a single institution experience. Leukemia & Lymphoma 58:3, pages 740-742.
Read now
Read now
Laetitia Souchet-Compain, Stéphanie Nguyen, Sylvain Choquet & Véronique Leblond. (2013) Fludarabine in Waldenstrom’s macroglobulinemia. Expert Review of Hematology 6:3, pages 229-237.
Read now
Read now
Pasquale Niscola, Gisella Vischini, Andrea Tendas, Laura Scaramucci, Marco Giovannini, Francesco Bondanini, Claudio Romani, Gregorio Antonio Brunetti, Claudio Cartoni, Luca Cupelli, Michele Ferrannini, Alessio Perrotti, Giovanni Del Poeta, Roberto Palumbo & Paolo de Fabritiis. (2011) Management of hematological malignancies in patients affected by renal failure. Expert Review of Anticancer Therapy 11:3, pages 415-432.
Read now
Read now
Ann Janssens, Marc Boogaerts & Gregor Verhoef. (2009) Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia. Drug Design, Development and Therapy 3, pages 241-252.
Read now
Read now
Xiaoyan Ding, Alexandra A Herzlich, Rachel Bishop, Jingsheng Tuo & Chi-Chao Chan. (2008) Ocular toxicity of fludarabine: a purine analog. Expert Review of Ophthalmology 3:1, pages 97-109.
Read now
Read now
Thomas Elter, Michael Hallek & Andreas Engert. (2006) Fludarabine in chronic lymphocytic leukaemia. Expert Opinion on Pharmacotherapy 7:12, pages 1641-1651.
Read now
Read now
Articles from other publishers (43)
Dimitrios Filioglou, Muhammad Husnain, Sharad Khurana, Richard J. Simpson & Emmanuel Katsanis. (2023) Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?. Frontiers in Immunology 14.
Crossref
Crossref
Franziska Marquard, Claudia Langebrake, Dietlinde Janson, Maida Mahmud, Adrin Dadkhah, Nicolaus Kröger & Francis Ayuk. (2023) Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment. Frontiers in Oncology 13.
Crossref
Crossref
Meletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, Nelson Leung, Joseph Mikhael, Simon J Harrison, Efstathios Kastritis, Laurent Garderet, Alessandro Gozzetti, Niels W C J van de Donk, Katja C Weisel, Ashraf Z Badros, Meral Beksac, Jens Hillengass, Mohamad Mohty, P Joy Ho, Ioannis Ntanasis-Stathopoulos, Maria-Victoria Mateos, Paul Richardson, Joan Blade, Philippe Moreau, Jesus San-Miguel, Nikhil Munshi, S Vincent Rajkumar, Brian G M Durie, Heinz Ludwig & Evangelos Terpos. (2023) Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. The Lancet Oncology 24:7, pages e293-e311.
Crossref
Crossref
Jasneet Kaur, Sai Sudha Valisekka, Maha Hameed, Pushyami Satya Bandi, Samyukta Varma, Chibuzor Joseph Onwughalu, Hany Ibrahim & Himani Mongia. (2023) Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review. Clinical Lymphoma Myeloma and Leukemia 23:5, pages e195-e212.
Crossref
Crossref
Israr Khan, Nida Khan, Natalie Wolfson, Kawthar Djebabria, Mohammad Ebad Ur Rehman & Faiz Anwer. (2023) Safety of CAR-T Cell Therapy in Patients With Renal Failure/Acute Kidney Injury: Focused Review. Clinical Hematology International 5:2-3, pages 122-129.
Crossref
Crossref
Anthony C. Wood, Ariel Perez Perez, Brian Arciola, Kedar Patel, Grace Johnson, Elizabeth DiMaggio, Christina A. Bachmeier, Kayla Reid, Salvatore Carallo, Melanie H. Vargas, Rawan Faramand, Julio C. Chavez, Bijal Shah, Sameh Gaballa, Farhad Khimani, Hany Elmariah, Taiga Nishihori, Aleksandr Lazaryan, Ciara Freeman, Marco L. Davila, Frederick L. Locke, Rahul Mhaskar, Claude Bassil & Michael D. Jain. (2022) Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplantation and Cellular Therapy 28:12, pages 829.e1-829.e8.
Crossref
Crossref
Hajime Yasuda, Mutsuko Yasuda & Norio Komatsu. (2021) Chemotherapy for non‐Hodgkin lymphoma in the hemodialysis patient: A comprehensive review. Cancer Science 112:7, pages 2607-2624.
Crossref
Crossref
Jorge J. Castillo, Natalie S. Callander, Muhamed Baljevic, Douglas W. Sborov & Shaji Kumar. (2021) The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. American Journal of Hematology 96:7, pages 846-853.
Crossref
Crossref
Joseph Bubalo. 2021. Blood and Marrow Transplant Handbook. Blood and Marrow Transplant Handbook
85
101
.
XiaoLe Han, Hao Hao, QingYu Li, ChenYin Liu, JiaWen Lei, Fan Yu, Ke Chen, Yi Liu & Tao Huang. (2020) The interaction mechanism between fludarabine and human serum albumin researched by comprehensive spectroscopic methods and molecular docking technique. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 233, pages 118170.
Crossref
Crossref
Qin Cao, Huimeng Qi, Li Yao & Qiang Liu. (2020) Monoclonal gammopathy of renal significance: clinical manifestation, pathogenic characteristic and treatment. Panminerva Medica 62:1.
Crossref
Crossref
SABINE KARAM, VICTORIA GUTGARTS & ILYA GLEZERMAN. 2020. Onco-Nephrology. Onco-Nephrology
183
196.e7
.
Stuart M. Lichtman. 2020. Geriatric Oncology. Geriatric Oncology
861
880
.
Hyewon Chung, Kyung Taek Hong, Ji Won Lee, Su-jin Rhee, Seokuee Kim, Seo Hyun Yoon, Kyung-Sang Yu & Hyoung Jin Kang. (2018) Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients. Bone Marrow Transplantation 54:2, pages 284-292.
Crossref
Crossref
Lily Yan & Alison Gulbis. 2019. Hematopoietic Cell Transplantation for Malignant Conditions. Hematopoietic Cell Transplantation for Malignant Conditions
37
57
.
Stuart M. Lichtman. 2019. Geriatric Oncology. Geriatric Oncology
1
20
.
Vijay Ivaturi, Christopher C. Dvorak, Danna Chan, Tao Liu, Morton J. Cowan, Justin Wahlstrom, Melisa Stricherz, Cathryn Jennissen, Paul J. Orchard, Jakub Tolar, Sung-Yun Pai, Liusheng Huang, Francesca Aweeka & Janel Long-Boyle. (2017) Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation 23:10, pages 1701-1713.
Crossref
Crossref
Kinjal Sanghavi, Anthony Wiseman, Mark N. Kirstein, Qing Cao, Richard Brundage, Kyle Jensen, John Rogosheske, Andy Kurtzweil, Janel Long-Boyle, John Wagner, Erica D. Warlick, Claudio G. Brunstein, Daniel J. Weisdorf & Pamala A. Jacobson. (2016) Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. Translational Research 175, pages 103-115.e4.
Crossref
Crossref
Yi-Bin Chen, Tatsuo Kawai & Thomas R. Spitzer. (2016) Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance. Advances in Hematology 2016, pages 1-8.
Crossref
Crossref
Valentin Goede & Michael Hallek. (2015) Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope. Drugs & Aging 32:11, pages 877-886.
Crossref
Crossref
Joseph S. Bubalo. 2015. Blood and Marrow Transplant Handbook. Blood and Marrow Transplant Handbook
67
80
.
Megan N. Bodge, Srividya Reddy, Michael Scott Thompson & Bipin N. Savani. (2014) Preparative Regimen Dosing for Hematopoietic Stem Cell Transplantation in Patients with Chronic Kidney Disease: Analysis of the Literature and Recommendations. Biology of Blood and Marrow Transplantation 20:7, pages 908-919.
Crossref
Crossref
Jean-Paul FermandFrank BridouxRobert A. KyleEfstathios KastritisBrendan M. WeissMark A. Cook, Mark T. DraysonAngela DispenzieriNelson Leung. (2013) How I treat monoclonal gammopathy of renal significance (MGRS). Blood 122:22, pages 3583-3590.
Crossref
Crossref
Joshua Lukenbill & Matt Kalaycio. (2013) Fludarabine: A review of the clear benefits and potential harms. Leukemia Research 37:9, pages 986-994.
Crossref
Crossref
Tali M. Johnson. (2012) Treatment and Management of Chronic Lymphocytic Leukemia in the Elderly: What the Pharmacist Clinician Should Know. The Consultant Pharmacist 27:4, pages 274-285.
Crossref
Crossref
Hong Seok Choi, Sung-Yong Kim, Jong-Ho Lee, So Young Yoon, Yo-Han Cho & Hong Ghi Lee. (2011) Successful Allogeneic Stem-Cell Transplantation in a Patient With Myelodysplastic Syndrome With Hemodialysis-Dependent End-Stage Renal Disease. Transplantation 92:6, pages e28-e29.
Crossref
Crossref
J R Long-Boyle, K G Green, C G Brunstein, Q Cao, J Rogosheske, D J Weisdorf, J S Miller, J E Wagner, P B McGlave & P A Jacobson. (2010) High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplantation 46:1, pages 20-26.
Crossref
Crossref
Eliot C. Heher & Thomas R. Spitzer. (2010) Hematopoietic Stem Cell Transplantation in Patients With Chronic Kidney Disease. Seminars in Nephrology 30:6, pages 602-614.
Crossref
Crossref
Stuart M Lichtman. (2009) Chemotherapy in the elderly: are their needs being met?. Therapy 6:6, pages 893-902.
Crossref
Crossref
Andrea Tendas, Luca Cupelli, Teresa Dentamaro, Laura Scaramucci, Roberto Palumbo, Pasquale Niscola, Marco Giovannini, Daniela Piccioni, Alessio Pio Perrotti & Paolo de Fabritiis. (2008) Feasibility of a dose-adjusted fludarabine–melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma. Annals of Hematology 88:3, pages 285-286.
Crossref
Crossref
Lev ShvidelMirel CohnErica Sigler. (2009) Pharmacotherapy Update: Fludarabine in the Treatment of Non-Hodgkin's Lymphoma. Clinical Medicine. Therapeutics 1, pages CMT.S2553.
Crossref
Crossref
Supriya Mohile, Nail Nagovskiy & Lodovico Balducci. 2009. Geriatric Oncology. Geriatric Oncology
201
261
.
Stuart M. Lichtman & Manpreet K. Boparai. (2008) Anticancer Drug Therapy in the Older Cancer Patient: Pharmacology and Polypharmacy. Current Treatment Options in Oncology 9:2-3, pages 191-203.
Crossref
Crossref
Mitchell E. Horwitz, Ivan Spasojevic, Ashley Morris, Marilyn Telen, James Essell, Cristina Gasparetto, Keith Sullivan, Gwynn Long, John Chute, Nelson Chao & David Rizzieri. (2007) Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and Pharmacokinetics. Biology of Blood and Marrow Transplantation 13:12, pages 1422-1426.
Crossref
Crossref
Stuart M. Lichtman, Hans Wildiers, Etienne Chatelut, Christopher Steer, Daniel Budman, Vicki A. Morrison, Brigitte Tranchand, Iuliana Shapira & Matti Aapro. (2007) International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients—An Analysis of the Medical Literature. Journal of Clinical Oncology 25:14, pages 1832-1843.
Crossref
Crossref
Stuart M. Lichtman, Hans Wildiers, Vincent Launay-Vacher, Christopher Steer, Etienne Chatelut & Matti Aapro. (2007) International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. European Journal of Cancer 43:1, pages 14-34.
Crossref
Crossref
Mark N. Polizzotto, Constantine S. Tam, Alvin Milner, E. Henry Januszewicz, H. Miles Prince, David Westerman, Max M. Wolf & John F. Seymour. (2006) The influence of increasing age on the deliverability and toxicity of fludarabine‐based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer 107:4, pages 773-780.
Crossref
Crossref
Jan T. Kielstein, Michael Stadler, David Czock, Frieder Keller, Bernd Hertenstein & Jorg Radermacher. (2005) Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure. European Journal of Haematology 74:6, pages 533-534.
Crossref
Crossref
Steven Gabardi & Stuart Abramson. (2005) Drug Dosing in Chronic Kidney Disease. Medical Clinics of North America 89:3, pages 649-687.
Crossref
Crossref
Constantine S. Tam, Max M. Wolf, E. Henry Januszewicz, Andrew P. Grigg, H. Miles Prince, David Westerman & John F. Seymour. (2004) A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer 101:9, pages 2042-2049.
Crossref
Crossref
James H. Doroshow & Timothy Synold. 2003. Thomas' Hematopoietic Cell Transplantation. Thomas' Hematopoietic Cell Transplantation
130
157
.
Amy J. Johnson, Andrew P. Mone, Vivek Abhyankar & John C. Byrd. (2003) Advances in the therapy of chronic lymphocytic leukemia. Current Opinion in Hematology 10:4, pages 297-305.
Crossref
Crossref
Veena John, Sandeep Mashru & Stuart M Lichtman. (2003) Pharmacological Factors Influencing Anticancer Drug Selection in the Elderly. Drugs & Aging 20:10, pages 737-759.
Crossref
Crossref